These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24236917)

  • 21. The FDA's enforcement of IRBs and patient informed consent.
    Kelsey FO
    Food Drug Cosmet Law J; 1989 Jan; 44(1):13-20. PubMed ID: 11651627
    [No Abstract]   [Full Text] [Related]  

  • 22. The FDA's generic-drug approval process: similarities to and differences from brand-name drugs.
    Kefalas CH; Ciociola AA
    Am J Gastroenterol; 2011 Jun; 106(6):1018-21. PubMed ID: 21637264
    [No Abstract]   [Full Text] [Related]  

  • 23. When is a medical product too risky? An interview with FDA's top drug official. Interview by Tamar Nordenberg.
    Woodcock J
    FDA Consum; 1999; 33(5):8-11, 13. PubMed ID: 10522164
    [No Abstract]   [Full Text] [Related]  

  • 24. Highlights and a hidden hazard--the FDA's new labeling regulations.
    Avorn J; Shrank W
    N Engl J Med; 2006 Jun; 354(23):2409-11. PubMed ID: 16760439
    [No Abstract]   [Full Text] [Related]  

  • 25. The importance of patent term restoration to pharmaceutical innovation.
    Hutt PB
    Health Aff (Millwood); 1982; 1(2):6-24. PubMed ID: 7185724
    [No Abstract]   [Full Text] [Related]  

  • 26. FDA's regulation of prescription drug labeling: a role for implied preemption.
    Kendrick LC
    Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031
    [No Abstract]   [Full Text] [Related]  

  • 27. U.S. Food and Drug Administration. "Evaluation Criteria" for Difficult to Compound Drugs.
    Allen LV
    Int J Pharm Compd; 2015; 19(6):487-8. PubMed ID: 26891563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Issues in bringing new drugs to the market.
    Tracey WR
    Science; 2005 Dec; 310(5753):1425-6; author reply 1425-6. PubMed ID: 16329172
    [No Abstract]   [Full Text] [Related]  

  • 29. The FDA's response to AIDS: paradigm shift in new drug policy?
    Podraza R
    Food Drug Law J; 1993; 48(3):351-75. PubMed ID: 11653267
    [No Abstract]   [Full Text] [Related]  

  • 30. A timely re-examination of drug polymorphism in pharmaceutical development and regulation.
    Grant DJ; Byrn SR
    Adv Drug Deliv Rev; 2004 Feb; 56(3):237-9. PubMed ID: 14962580
    [No Abstract]   [Full Text] [Related]  

  • 31. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
    Dorfman HL; Quinn VM; Brophy EA
    Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
    [No Abstract]   [Full Text] [Related]  

  • 32. Rational and efficient geometric definition of pharmacophores is essential for the patent process.
    Guérin GA; Pratuangdejkul J; Alemany M; Launay JM; Manivet P
    Drug Discov Today; 2006 Nov; 11(21-22):991-8. PubMed ID: 17055408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Linking a policy on nonformulary drugs to the FDA's therapeutic-potential classification system.
    Poirier TI; Vorbach M; Bache T
    Am J Hosp Pharm; 1994 Sep; 51(18):2277-8. PubMed ID: 7801989
    [No Abstract]   [Full Text] [Related]  

  • 34. Upon closer inspection. As the U.S. imports more drugs and devices, the FDA's overseas initiatives aim to head off trouble at the source.
    Rhea S
    Mod Healthc; 2009 Mar; 39(13):28-30. PubMed ID: 19405431
    [No Abstract]   [Full Text] [Related]  

  • 35. USAN and FDA.
    Am J Pharm Sci Support Public Health; 1966; 138(5):172-4. PubMed ID: 5976320
    [No Abstract]   [Full Text] [Related]  

  • 36. Sending pharma better signals.
    Avorn J
    Science; 2005 Jul; 309(5735):669. PubMed ID: 16051753
    [No Abstract]   [Full Text] [Related]  

  • 37. The cost of drugs.
    N Z Med J; 1969 Jan; 69(440):33-4. PubMed ID: 4974999
    [No Abstract]   [Full Text] [Related]  

  • 38. Face-off will new drugs pay off in time to counter patent losses for Forest Laboratories?
    Vukhac K; Rivkind I
    Fortune; 2012 Jun; 165(8):80. PubMed ID: 22741415
    [No Abstract]   [Full Text] [Related]  

  • 39. How companies stall generics and keep themselves healthy.
    Stolberg SG; Gerth J
    N Y Times Web; 2000 Jul; ():A1, A14, A15. PubMed ID: 11785519
    [No Abstract]   [Full Text] [Related]  

  • 40. The bugaboo of generic names and drug patents.
    TAYLOR R
    Appl Ther; 1963 May; 5():403-4. PubMed ID: 13980361
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.